Modality
Nanobody
MOA
CD47i
Target
KRASG12D
Pathway
RAS/MAPK
Atopic Derm
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
Jul 2020
→ Jan 2026
Phase 1Current
NCT04549613
2,335 pts·Atopic Derm
2020-07→2026-01·Not yet recruiting
2,335 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-083mo agoPh2 Data· Atopic Derm
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P1/2
Not yet…
Catalysts
Ph2 Data
2026-01-08 · 3mo ago
Atopic Derm
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04549613 | Phase 1/2 | Atopic Derm | Not yet recr... | 2335 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Zenonesiran | GSK | Preclinical | DLL3 |